secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193805-26-000370
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints Jon Congleton, Mineralys CEO and ex-Teva exec, to Board
------------------------------------------------------------------------

- Jon Congleton appointed to Board as Class II director effective March 27, 2026; Board size increased from 8 to 9.
- Congleton will chair Compensation Committee; received initial grant of options for 500,000 shares vesting over 3 years.
- Congleton brings nearly 40 years of biopharma experience; currently CEO of Mineralys Therapeutics.
- He previously led the U.S. launch of Copaxone at Teva and held senior roles at Impel NeuroPharma and Nivalis Therapeutics.
- Appointment supports Immunic's transition to commercial stage for MS drug vidofludimus calcium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000370/0001193805-26-000370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000370/e665296_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer